Loading
CSA Medical Inc. completed an oversubscribed $53 million Series D preferred stock equity financing. The funding round was co-led by TVM Capital Life Science and Yonjin Ventures, with participation from existing shareholders SV Health Investors, Ascension Ventures, First Analysis, Blue Heron, and Intersouth Partners.
The company is developing the RejuvenAir® System, a medical device that uses liquid nitrogen spray cryotherapy for the treatment of chronic bronchitis, a subset of Chronic Obstructive Pulmonary Disease (COPD). The funds are intended to support the company through the U.S. Food and Drug Administration (FDA) premarket approval (PMA) process and to build a comprehensive commercialization strategy for a successful U.S. launch of the RejuvenAir System. The RejuvenAir System is designed to target and destroy damaged cells in the airways without creating scar tissue, allowing for the regrowth of healthy cells.
Funding Round: Series D
Amount Raised: $53M
Valuation: Unknown
Lead Investor: TVM Capital Life Science, Yonjin Venture
Other Funds that Invested: SV Health Investors, Ascension Ventures, First Analysis, Blue Heron, Intersouth Partners
Company Industry: Medical Devices
Company Headquarters: Lexington, Massachusetts, United States
Join thousands of founders using our technology to find the right investors and close rounds faster than ever before.